Clinical Trial Update: Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating GB-4362 in combination with Enfortumab Vedotin and Pembrolizumab for urothelial carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• GB-4362
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Generate Biomedicines | Conditions: Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | Phase 1 | Status: RECRUITING